Glaxo Q3 top-line down 8%, Shingrix sales drop 30%, Eliipta sales +21%

• GlaxoSmithKline (GSK) Q3 results (£):
• Revenues: 8,646M (-7.9%); Pharmaceuticals: 4,192M (-7.5%); Vaccines: 2,032M (-12.0%); Consumer Healthcare: 2,422M (-4.1%).
• Key product sales: Shingrix: 374M (-30%); Ellipta: 727M (+21%); Tivicay: 377M (-15%); Triumeq: 577M (-11%); Nucala: 251M (+24%); Benlysta: 186M (+8%); Seretide/Advair: 368M (-12%); Ventolin: 177M (-23%); Augmentin: $106M (-30%); Bexsero: 219M (-14%); Infanrix, Pediarix: 158M (-21%); Rotarix: 132M (-21%); Juluca: 123M (+22%).
• Net Income: 1,244M (-19.8%); EPS: 0.25 (-19.4%); non-GAAP Net Income: 1,775M (-7.1%); non-GAAP EPS: 0.36 (-7.7%).
• CF Ops: 4,586M (+0.4%).
• During Q3, the company has seen a recovery in vaccination rates, returning to prior year levels.
• The Company is on track to deliver FY2020 non-GAAP EPS at the lower end of (1%) to (4%) range at CER, supported by strong commercial execution of key growth products and disciplined cost control along with sustained recovery of adult immunization rates, particularly in Shingrix.
• https://seekingalpha.com/news/3627219-gsk-gsk-q3-top-line-down-8-shingrix-sales-drop-30-eliipta-salesplus-21